GU Cancers 2019 | RANGE: ramucirumab plus docetaxel for urothelial cancer
Jeanny Aragon-Ching, MD, FACP, of the Inova Schar Cancer Institute, Fairfax, VA, discusses the results from the RANGE study (NCT02426125) of ramucirumab plus docetaxel in advanced or metastatic urothelial cancers. This interview was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.
Transcript (edited for clarity)
RANGE is actually a Phase III trial looking at the utility of ramucirumab, which is a monoclonal antibody against VEGF-R2, in combination with docetaxel in a patient population of previously treated, locally advanced,
RANGE is actually a Phase III trial looking at the utility of ramucirumab, which is a monoclonal antibody against VEGF-R2, in combination with docetaxel in a patient population of previously treated, locally advanced, metastatic urothelial cancer. These were pretreated patients, prior failures with chemotherapy, although there were a subset of patients who actually got checkpoint inhibitors. This particular trial that was being presented at ASCO GU actually looked at the relationship between ramucirumab exposure as well as response. There were a lot of sophisticated analysis that was done looking at exposure and response, and what they found was when they categorized all the exposures into different quartiles – quartile one, two, three, and four, patients who achieved the highest quartile of response also tended to have the best overall survival. Now, this was more like a pharmacokinetic analysis, meaning they looked at the drug exposure and they deemed that it correlated with overall survival.
Read more...
